Overview
Patients with moderate or severe CMV disease less than 21 days old who have a maternal donor who has a CMV response to the peptivators will be screened.
All patients will receive treatment with valganciclovir or ganciclovir. There is a safety run in with treatment with CMV CTLs in cohort 1 and if found to be safe, will proceed to cohort 2 for randomization to receive antiviral therapy with or without CMV CTLs.
Funding source: FDA OOPD
Description
Given the vulnerability and poor outcomes of preterm neonates and neonates in general to viral infection, including the need for prolonged antiviral therapy for 6 or more months to achieve just modest improvements in sensorineural functions, CMV CTL therapy offers a promising alternative. CMV CTL treatment will build on the hosts innate immune capacity to create a more effective and permanent defense against collateral injury arising from CMV infections.
Patients who meet all inclusion/exclusion criteria with a maternal donor who meet all donor criteria will be enrolled onto study.
Cohort 1 is a safety run-in; the first 3 patients enrolled will be treated with anti-viral and CMV CTLs. The external DSMB will review the data from the first patient, and if there are no adverse events or dose-limiting toxicities observed, approve patient 2, and then 3, 28 days after the prior patients last CTL infusion. Assuming there are no adverse events in any of the first 3 patients, the study will proceed to Cohort 2.
Cohort 2 will be randomized 1:1 to either anti-viral treatment alone or anti-viral treatment plus CMV CTLs.
Patients who are randomized to receive CMV CTLs will get their first infusion on Day 0. If the patient fails to achieve a CR, they may receive one infusion every 2 weeks up to 5 maximum CMV CTL infusions as long as there are no DLTs or AEs observed
Eligibility
Inclusion Criteria:
- Age: ≤ 21 days of life
- Birth Weight: ≥ 2500 gms
- Gestational age: ≥ 34 weeks of age
- Diagnosis of CMV viremia, viruria, and/or infection:Either one or more:
Elevated CMV by RT-PCR in urine, saliva, CSF, or plasma; and/or Positive urine culture for
CMV
- Moderate or Severe CMV Disease
Any one or more of the following attributable to congenital CMV infection:
- Thrombocytopenia (≤ 50,000 mm3)
- Multiple petechiae
- Hepatomegaly
- Splenomegaly
- Intrauterine growth retardation
- Increased transaminases
- Increased bilirubin
- Microcephaly
- Ventriculomegaly
- Intracerebral calcifications
- Periventricular echogenicity
- Cortical or cerebral malformation
- Chorioretinitis
- Severe neonatal hearing loss
- CMV DNA by PCR in CNS
- Increased WBC for age in CNS
- Minimal Organ Criteria Hematological: ANC ≥ 750/mm3, HgB ≥ 8gm/dl, Platelets ≥
20,000/kmm3 Renal: Serum creatinine ≤ 1.0 mg/dl Hepatic: ALT/SGOT ≤3x upper
normal limits
- Donor Availability: Maternal donor available with a T-cell response CMV MACS®
PepTivators. the donor is considered suitable if the percentage of IFN-gamma+ T
cells is > 0.01% after stimulation with PepTivators.
Exclusion Criteria -
- Patient receiving steroids (> 0.5 mg/kg prednisone equivalent) on the same day of CMV
CTL infusion. Antenatal steroids for lung maturation will have been cleared prior to
CMV diagnosis.
- Concomitant enrollment in another experimental clinical trial investigating the
treatment of neonatal CMV viremia and/or infection.
- Any medical condition that could compromise participation in the study according to
the investigator's assessment.
- Known history of HIV infection in the mother.
- Patient's legally authorized representative unwilling or unable to comply with the
protocol or unable to give informed consent.